BRPI0815059A2 - Derivado de 1,3-di-hidroisoindol - Google Patents
Derivado de 1,3-di-hidroisoindolInfo
- Publication number
- BRPI0815059A2 BRPI0815059A2 BRPI0815059-1A2A BRPI0815059A BRPI0815059A2 BR PI0815059 A2 BRPI0815059 A2 BR PI0815059A2 BR PI0815059 A BRPI0815059 A BR PI0815059A BR PI0815059 A2 BRPI0815059 A2 BR PI0815059A2
- Authority
- BR
- Brazil
- Prior art keywords
- hydroisoindol
- derivative
- hydroisoindol derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007041116A DE102007041116A1 (de) | 2007-08-30 | 2007-08-30 | 1,3-Dihydro-isoindolderivate |
| PCT/EP2008/006198 WO2009030316A1 (de) | 2007-08-30 | 2008-07-28 | 1,3-dihydro-isoindolderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0815059A2 true BRPI0815059A2 (pt) | 2015-02-10 |
Family
ID=40029128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0815059-1A2A BRPI0815059A2 (pt) | 2007-08-30 | 2008-07-28 | Derivado de 1,3-di-hidroisoindol |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8183279B2 (pt) |
| EP (1) | EP2181092B1 (pt) |
| JP (1) | JP5529739B2 (pt) |
| KR (1) | KR20100061817A (pt) |
| CN (1) | CN101790513A (pt) |
| AR (1) | AR070649A1 (pt) |
| AU (1) | AU2008295176B2 (pt) |
| BR (1) | BRPI0815059A2 (pt) |
| CA (1) | CA2697934C (pt) |
| DE (1) | DE102007041116A1 (pt) |
| EA (1) | EA201000362A1 (pt) |
| ES (1) | ES2532853T3 (pt) |
| IL (1) | IL204126A (pt) |
| MX (1) | MX2010002042A (pt) |
| WO (1) | WO2009030316A1 (pt) |
| ZA (1) | ZA201002217B (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| AU2013266086B2 (en) | 2012-05-25 | 2018-03-01 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
| US9938236B2 (en) * | 2012-12-27 | 2018-04-10 | Drexel University | Antiviral agents against HBV infection |
| WO2015188198A2 (en) | 2014-06-06 | 2015-12-10 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta |
| CN106795141A (zh) * | 2014-07-08 | 2017-05-31 | Viiv保健英国有限公司 | 用于治疗病毒感染的异吲哚啉衍生物 |
| US10316167B2 (en) * | 2014-09-19 | 2019-06-11 | Plastipak Packaging | Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions |
| WO2017131500A1 (ko) * | 2016-01-29 | 2017-08-03 | 계명대학교 산학협력단 | Hsp90 억제 활성을 갖는 신규 화합물 또는 이의 약제학적으로 허용가능한 염 및 이의 의학적 용도 |
| EP3478686B1 (en) * | 2016-06-29 | 2020-04-15 | H. Hoffnabb-La Roche Ag | Novel dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| CN106366089B (zh) * | 2016-08-19 | 2019-06-11 | 爱斯特（成都）生物制药股份有限公司 | 二氢异吲哚衍生物及其类似物的制备方法 |
| EP3568128B1 (en) * | 2017-01-12 | 2022-07-06 | The University of Kansas | Hsp90b n-terminal isoform-selective inhibitors |
| EP4573087A1 (en) * | 2022-08-21 | 2025-06-25 | University of Notre Dame du Lac | Use of (isoindolin-2-yl)(4-hydroxy-3-(isoindoline-2-carbonyl)phenyl)methanones in the treatment of tumor necrosis factor receptor-associated protein 1 dysfunction |
| CN117402075B (zh) * | 2023-10-17 | 2026-01-09 | 厦门大学深圳研究院 | 一种具有特异性抗肿瘤活性的可见光响应的人工h+/ci-离子通道的制备 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
| WO1999051223A1 (en) | 1998-04-03 | 1999-10-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke |
| EP1161231A2 (en) | 1999-03-12 | 2001-12-12 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH | Method of inhibiting a chaperone protein |
| CA2429196A1 (en) | 2000-03-24 | 2001-10-04 | Duke University | Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
| WO2002002123A1 (en) | 2000-06-29 | 2002-01-10 | Trustees Of Boston University | Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders |
| EP1322325A4 (en) | 2000-07-20 | 2004-09-15 | Merck & Co Inc | INHIBITION OF PROCESSING AND REPLICATION OF HEPATITIS C VIRUS |
| ATE526019T1 (de) | 2000-07-28 | 2011-10-15 | Sloan Kettering Inst Cancer | Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen |
| AU2002255263B2 (en) | 2001-04-16 | 2006-12-14 | Eisai R&D Management Co., Ltd. | Novel 1H-indazole compound |
| EP1450784A4 (en) | 2001-11-09 | 2005-02-09 | Conforma Therapeutics Corp | HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE |
| AU2005266494B2 (en) | 2004-07-27 | 2009-09-10 | Novartis Ag | Inhibitors of Hsp90 |
| EP1883402A2 (en) | 2005-04-13 | 2008-02-06 | Astex Therapeutics Limited | Hydroxybenzamide derivatives and their use as inhibitors of hsp90 |
| US20090215742A1 (en) | 2005-05-03 | 2009-08-27 | Pfizer, Inc. | Amide resorcinol compounds |
-
2007
- 2007-08-30 DE DE102007041116A patent/DE102007041116A1/de not_active Withdrawn
-
2008
- 2008-07-28 BR BRPI0815059-1A2A patent/BRPI0815059A2/pt not_active Application Discontinuation
- 2008-07-28 AU AU2008295176A patent/AU2008295176B2/en not_active Ceased
- 2008-07-28 ES ES08785148.1T patent/ES2532853T3/es active Active
- 2008-07-28 US US12/675,410 patent/US8183279B2/en not_active Expired - Fee Related
- 2008-07-28 EA EA201000362A patent/EA201000362A1/ru unknown
- 2008-07-28 CA CA2697934A patent/CA2697934C/en not_active Expired - Fee Related
- 2008-07-28 CN CN200880104684A patent/CN101790513A/zh active Pending
- 2008-07-28 JP JP2010522201A patent/JP5529739B2/ja not_active Expired - Fee Related
- 2008-07-28 MX MX2010002042A patent/MX2010002042A/es not_active Application Discontinuation
- 2008-07-28 KR KR1020107006638A patent/KR20100061817A/ko not_active Withdrawn
- 2008-07-28 WO PCT/EP2008/006198 patent/WO2009030316A1/de not_active Ceased
- 2008-07-28 EP EP08785148.1A patent/EP2181092B1/de not_active Not-in-force
- 2008-08-29 AR ARP080103758A patent/AR070649A1/es unknown
-
2010
- 2010-02-23 IL IL204126A patent/IL204126A/en not_active IP Right Cessation
- 2010-03-29 ZA ZA2010/02217A patent/ZA201002217B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009030316A1 (de) | 2009-03-12 |
| EP2181092B1 (de) | 2015-01-14 |
| AU2008295176B2 (en) | 2013-05-02 |
| AR070649A1 (es) | 2010-04-28 |
| US8183279B2 (en) | 2012-05-22 |
| AU2008295176A1 (en) | 2009-03-12 |
| EA201000362A1 (ru) | 2010-08-30 |
| MX2010002042A (es) | 2010-03-15 |
| ZA201002217B (en) | 2017-11-29 |
| ES2532853T3 (es) | 2015-04-01 |
| US20100311745A1 (en) | 2010-12-09 |
| JP2010536893A (ja) | 2010-12-02 |
| CN101790513A (zh) | 2010-07-28 |
| JP5529739B2 (ja) | 2014-06-25 |
| KR20100061817A (ko) | 2010-06-09 |
| DE102007041116A1 (de) | 2009-03-05 |
| CA2697934C (en) | 2016-02-16 |
| CA2697934A1 (en) | 2009-03-12 |
| EP2181092A1 (de) | 2010-05-05 |
| IL204126A (en) | 2015-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR24C1047I2 (fr) | Derive de 4-pyrimidinesulfamide | |
| BRPI0811718A2 (pt) | Derivados de 3,3-espiroindolinona | |
| ATE502012T1 (de) | 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivat | |
| BRPI0816970A2 (pt) | 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas | |
| ATE555107T1 (de) | 2-aza-bicyclo-ä2,2,1-üheptan-derivate | |
| ATE469145T1 (de) | 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl- | |
| EP2226315A4 (en) | 2-aminoquinazoline DERIVATIVE | |
| BRPI0907563A2 (pt) | Derivados de 4,5-di-hidro-xazol-2-il amina | |
| ATE481383T1 (de) | 3-aza-bicycloä3.1.0ühexanderivate | |
| HRP20151058T1 (xx) | Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe | |
| BRPI0813707A2 (pt) | Derivados de pirimidinil-piridazinona | |
| BRPI0820112A2 (pt) | Derivados de isoxazol-piridina | |
| BRPI0809992A2 (pt) | Derivados de pirrolopirimidina | |
| BRPI0815717A2 (pt) | Compostos de imidazopirazina. | |
| ATE513831T1 (de) | Pyridinä3,4-büpyrazinone | |
| BRPI0820113A2 (pt) | Derivados de isoxazolo-piridazina | |
| BRPI0812155A2 (pt) | derivados de espiroindolinona | |
| BRPI0817935A2 (pt) | Derivados de biarila | |
| EP2072519A4 (en) | DIARYLKETIMINDERIVAT | |
| BRPI0814236A2 (pt) | Derivados de quinazolinamida | |
| BRPI0815059A2 (pt) | Derivado de 1,3-di-hidroisoindol | |
| BRPI0812518A2 (pt) | Derivados de indazolamida | |
| DE602007001681D1 (de) | 1,3-dioxan-carboxylsäuren | |
| BRPI0820649A2 (pt) | Derivados de isoxazalo-pirazina | |
| EP2344471A4 (en) | 7-PIPERIDINALKYL-3,4-dihydroquinolone DERIVATIVE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |